

## Antibodies Against Hepatitis C Virus (Anti-HCV) among Hemodialysis Patients in Makkah, Saudi Arabia

Ghanim Hamid Al-Khattabi<sup>1,\*</sup>

<sup>1</sup> Consultant of Preventive Medicine and Public Health, Epidemiologist; Preventive Medicine and Public Health Executive Administration, Ministry of Health, Makkah, Saudi Arabia

### ABSTRACT

Hepatitis C virus (HCV) infection is the most common cause of chronic liver disease in the world and evaluation of the epidemiology of HCV infection was made possible by the development of a serological assay to detect antibodies to epitopes of HCV. Hemodialysis (HD) is considered to be one of the main risk factors of HCV transmission. The prevalence of antibodies to HCV (anti-HCV) in patients undergoing maintenance dialysis therapy (MDT) was found to be one of the highest among different risk groups and there is wide variation in the prevalence of HCV infection among different dialysis units and countries. Therefore, the prevalence of anti-HCV was studied in patients undergoing MDT. The current study is a cross section one, where a sample of 361 HD patients were selected randomly from HD centers in three governmental hospitals in Makkah city and they were subjected to assessment for the prevalence of anti-HCV by using questionnaires in addition to clinical measurements. The overall prevalence of anti-HCV among HD patients was 49.9% according to clinical measurements and questionnaires. The overall prevalence of anti-HCV among HD patients in Makkah city (49.9%) was comparable to that reported from other parts of the Kingdom of Saudi Arabia (KSA) and it is almost similar to the already reported positivity rate of (43.2%) from the eastern region of KSA and southern regions of KSA (45.5%). However, strict adherence to universal precautions as recommended by the Center for Diseases Control (CDC), meticulous regular disinfection of HD machines, strict isolation of HCV-positive patients, dedicated dialysis machines and nursing staff at new dialysis set-up could possibly be the reasons of relatively low anti-HCV positivity at the current study than that reported by Shaheen *et al* [34], from four centers in the western region of KSA, (72.3%) and that by Huraib *et al* [29] in their multi-center study in KSA, (68%) as well as the mean national rate. On the other hand, the use of more sensitive third generation enzyme - linked immunosorbent assay (ELISA) technique, long duration on HD, multiple blood transfusions, patients with dialysis treatment in multi-centers, factors related to infrastructure, environment and operational system might be responsible for the high prevalence of anti-HCV found in this study than that reported by Saeed, et al from Riyadh and those observed in the central region of KSA. Although routes of transmission are still unclear, early detection of all infected patients is mandatory for HCV prophylaxis in HD patients. Furthermore, an intensive educational program for staff members, HD patients and proper evaluation of the HD situation are needed. Thus, observation of appropriate preventive measures by all HD-centers is paramount.

### Keywords:

Hepatitis C virus, Hemodialysis, Makkah, Saudi Arabia, Antibodies Against Hepatitis C Virus (Anti-HCV)

Received: 20 June 2022

Revised: 15 July 2022

Accepted: 27 July 2022

Published: 8 August 2022

\* Corresponding author.

E-mail address: [dralkhattabi@gmail.com](mailto:dralkhattabi@gmail.com)

<https://doi.org/10.37934/araset.27.1.6276>

## 1. Introduction

Hepatitis C virus (HCV) was first identified in 1989 by Choo *et al.* [1] HCV infection is a persistent public health concern in hemodialysis (HD) patients [2, 3] and is the most common cause of chronic liver disease in the world [4] and in HD patients[5]. HD patients are vulnerable to HCV infection because of the risk for exposure to HCV associated with the dialysis procedure [6]. In contrast with the hepatitis B virus (HBV), no vaccine is available for HCV [7]. Accurate testing for HCV is complicated by regional variation in the HCV genome and by variation in screening tests [7-10]. Patients infected with HCV often have minimal clinical evidence of disease [7, 9, 11]. HCV infection in end-stage renal disease (ESRD) patients has been associated with greater morbidity and mortality [9, 12, 13]. HCV infection has also been associated with greater morbidity and mortality in ESRD patients after they have received a renal transplant [14-16] and is particularly highly prevalent in developing countries [17].

There is wide variation in the prevalence of HCV infection among different dialysis units and countries as shown by Dialysis Outcomes and Practice Patterns Study (DOPPS)[18]. Approximately 170 million people in the world are infected with HCV[19]. The reported prevalence of anti-HCV antibody world-wide among dialysis patients has ranged from 1.7% [20] to 55% [21], from 1.7 to 70% [22], from 2% in northwestern Europe to 76.3% in Indonesia [23, 24] and from 29.4% to 65% in Brazil[25-28].

However, In Kingdom of Saudi Arabia (KSA), a positivity rate of HCV ranging between 14.5 and 94.7% has been reported[29]. Furthermore, studies from dialysis units in KSA have reported prevalence rates of 34.8% to 53.7%, 46.5%, 45.5% and 72.3% from the central[30, 31], eastern[32], southern[33], and western[34] regions, respectively. Other study conducted by Shaheen, *et al* [34] reported anti-HCV prevalence rate of 62.7% from Jeddah city and in a multi-center study of 22 HD units in KSA performed by Huraib *et al* [35] reported a prevalence rate ranging from 14.5 to 94.7%.[36]

Patients on long-term HD are considered to be a population at risk for HCV infection and the prevalence of anti-HCV in patients undergoing maintenance dialysis therapy (MDT) was found to be one of the highest among different risk groups[37]. Chronic HD is associated with both endemic cases and, more rarely, sporadic outbreaks of HCV infection[38]. Therefore, the prevalence of antibodies to HCV (anti-HCV) was studied in patients undergoing MDT.

HCV infection is of great clinical importance since: (a) it is commonly associated with chronic liver disease and cirrhosis [6] [39] [40] [41]. (b) it can lead to the development of hepatocellular carcinoma [42] [43]. (c) there is an increased risk of developing chronic liver disease in renal allograft recipients who are anti-HCV positive [44] [45, 46]. (d) till date, no vaccine has been developed for HCV. (e) there is an increased risk for development of chronic hepatitis in anti-HCV positive renal transplant recipients [47]. Although HCV-associated liver disease typically takes decades to become clinically manifest, a period of time much longer than the lifespan of most dialysis patients with a 5-yr survival of 60 to 70% , the liver disease–related complications seem the unlikely link to the high death risk[48]. However, the magnitude of HCV transmission within HD units is still unclear and therefore general recommendations for prevention have not been developed[3, 49, 50]. The Centre for Diseases Control (CDC) has made no recommendations for controlling HCV in HD units[3]. However, the natural course of HCV in HD patients is not well understood. It seems to differ from that in other HCV patients[51]. Liver function tests are close to or near normal in many cases,[52, 53] but the mortality of HCV infected HD patients seems to be enhanced compared with HCV negative HD patients in preliminary studies[54]. Thus, patients with HCV on chronic HD are at

increased risk of death, which suggests that the focus should be directed more to identification and prevention of HCV infection in HD patients.

Despite the importance of this topic, there is remarkable paucity in the studies which identify prevalence of anti-HCV in HD patients in KSA. This paucity was detected after extensive search using the key words (Hepatitis C virus, Hemodialysis, Saudi Arabia) in both Pub Med and Google Scholar. The aim of this study was to identify the prevalence of anti-HCV among HD patients at governmental kidney centers in Makkah city in KSA for the purpose of adopting practical measures to stop or minimize the spread of HCV infection among dialysis patients.

## 2. Materials and Methods

The current cross-sectional study was carried out in three HD centers at three major governmental hospitals in Makkah city which is located in the western region of KSA. The HD machines are always busy through the year with four shifts daily. Sometimes a fifth shift has to be arranged to overcome the heavy workload with large influx of patients during the Holy months of Ramadan and Hajj due to a large number of visitors from outside the city of Makkah and there is an arrangement for visitors who have ESRD and need dialysis to do it in governmental hospitals. Small HD units are also available in other governmental and private hospitals, which accommodate for only a small percentage of patients.

The study population represents patients registered in the three HD centers present in three major governmental hospitals in Makkah city. Their total number was estimated to be around 2000 patients at the time of the study; they included all patients with ESRD requiring HD and they are all registered in the HD units of kidney centers. Patients at the HD centers in the three hospitals undergo HD for an average of 3 times a week, with a small percentage undergoing HD only twice a week. The HD sessions usually take place in four shifts, from 7:30 A.M to 10:30 A.M, from 11:00 A.M to 2:00 P.M, from 2:30 P.M to 5:30 P.M and from 6:00 P.M to 9:00 P.M.

The sample size needed for estimating prevalence of anti-HCV was calculated by using Epi-Info program version 6.04; the required sample size was 385 patients. The responded who completed the participation accounted for 361; making a response rate of 93.8%. Inclusion criteria were any patient, conscious, understands, able to give an informed consent (if the patient was less than 18 years, the consent was taken from his parents) and regular on HD. Stratified sampling was conducted to ensure representativeness of male and female patients. Stratification was based on the available list of patients at each HD center in each hospital. This list cover patients from all wards, including male and female wards, the isolation section, both hepatitis C positive and negative patients and at different times of the day.

As the number of patients who were available at the time of the study accounted for 770 patients, an estimated sample size was 385 which represented one half of the patients; therefore, the estimation designated sample in each place was half of available listed patients as described in table one. The allocation of patients from each list was done by systematic sampling selecting every second patient in each list. There were separate lists for males and females which facilitated allocation of the sample by gender. Prevalence of anti-HCV in patients with ESRD was measured by a variety of methods. However, questionnaires and clinical measurements were used to measure prevalence of anti-HCV in HD patients.

A set of a structured questionnaire was developed by the researcher to ascertain information on patients' demographic characteristics and HCV status of patients and was translated into Arabic then it was back translated to ensure lexical equivalence. Additionally, it was subjected to validity testing after being translated into Arabic language and reviewed by consultant of family medicine,

consultant of community medicine and nephrology consultant. All patients underwent dialysis three times weekly. All units follow the same machine chemical disinfection protocols with no dialyzer reuse. The anti-HCV (Hepatitis C Virus Antibodies) assay was performed for every patient included in the study by using a third-generation enzyme-linked immunosorbent assay (ELISA) and for newly positive-case polymerase chain reaction (PCR) was performed for confirmation.

Dry weight (weight at the end of dialysis treatment) which is taken as the lowest tolerable weight at the end of dialysis treatment without the development of symptoms or hypotension, and the interdialytic weight gain (IDWG) is calculated as the difference between the patient's weight obtained at the onset of a dialysis treatment and the weight obtained at the end of the previous dialysis. The clinical measurements included biological measurements which included in addition to interdialytic weight gain (IDWG), biochemical markers which included pre-HD serum potassium or phosphorous levels and anti-HCV assay. Upon arrival to the dialysis centers, the physicians in charge were contacted and the researcher used to present the study design and explain the purpose of the research to the HD staff. Information regarding the HD center was obtained from the chief HD nurse. According to selection and inclusion criteria, designated patients were invited to participate in the study after explaining to them the purpose of the study.

Medical files of the patient were examined to check the weight of patients pre hemodialysis, weight of patients post hemodialysis (dry weight), number of co-morbid diseases and the presence of chronic diseases (such as DM, HTN), psychiatric diseases, hospitalization history, kidney transplant history, causes of kidney failure, hepatitis profile, potassium and phosphorus level, for how long is he or she on dialysis, number of daily tablet, others... These information were available for every patient as they are doing a monthly blood test examination pre and post hemodialysis session to evaluate the level of potassium, phosphorus and others chemical indicators.

Weight for each patient was measured before and after each HD sessions by well-trained nurses. The patient's weight at the beginning of dialysis session was subtracted from the weight at the end of previous dialysis session (dry weight) to calculate the interdialytic weight gain (IDWG); then this IDWG is divided by weight at the end of previous dialysis session (dry weight) to get IDWG percentage. A standard electronic weighing chair was used to obtain the weight. The scale was placed on a hard floor surface. Participants were asked to remove their heavy outer garments; female patients were weighed with Abaya (ladies body cover), and Abaya was weighed and its weight was subtracted from the total. Weight was measured in all participants and taken to the nearest 0.1 kg using weighing scale. The scale was calibrated at the beginning and end of each examining day. The scale was checked using the standardized weights and calibration was corrected if the error was greater than 0.1 kg.

The pilot study was carried out in Jeddah kidney center at King Fahd general hospital (referral center for HD patients in Western province) on about 10% of our sample size who were not included in the main study.

**Table 1**

Description of samples and responses from each hospital according to gender

	Al-Noor Specialist Hospital(ANSH)		King Abdul-Aziz Hospital(KAH)		King Fisal Hospital(KFH)	
	Male	Female	Male	Female	Male	Female
Available patients	518		162		90	
Available patients according to gender	266	252	74	88	28	62
Required sample of patients	133	126	37	44	14	31
Responded patients	125	118	34	41	13	30

Statistical Package for Social Science (SPSS) program, version 20 was used for statistical analysis of data. The level of statistical significance was set at  $P < 0.05$  throughout the study. Data was obtained after applying for ethical approval from the Ministry of Health & General Directorate of Health Affairs in Makkah city.

#### 4. Results

The current study included 361 patients. Table 2 demonstrates that the majority of patients (78.9%) aged <65 years, with a mean age of  $50.1 \pm 15.8$  years. There was almost equal distribution of males and females with an overwhelming majority of Saudis (93.9%). About two thirds of them were married (62.3%) and around one third (31.3%) were illiterate. The great majorities (88.9%) were unemployed and almost two thirds of the patients (60.1%) had monthly income between 1000 and 3000 SAR (Saudi Arabian Riyals).

**Table 2**  
Socio-demographic characteristics of the study group (n=361)

Characteristics	Frequency	%
<b>Age</b>		
Less than 65 years	285	78.9
65 years and older	76	21.1
Mean $\pm$ SD	50.1 $\pm$ 15.8	
Range	14-95	
<b>Gender</b>		
Male	172	47.6
Female	189	52.4
<b>Marital status</b>		
Married	225	62.3
Single	77	21.3
Others (divorced, widowed)	59	16.3
<b>Nationality</b>		
Saudi	339	93.9
Non-Saudi	22	6.1
<b>Education level</b>		
Illiterate	113	31.3
Primary school	89	24.7
Secondary school and above	159	44.0
<b>Employment</b>		
Employed	40	11.1
Not employed	321	88.9
<b>Monthly income</b>		
No income	30	8.3
Less than 1000 SAR*	16	4.4
From 1001 to 3000 SAR*	217	60.1
From 3001 to 6000 SAR*	57	15.8
From 6001 to 10000 SAR*	16	4.4
From 10001 to 15000 SAR*	14	3.9
From 15001 to 20000 SAR*	8	2.2
More than 20000 SAR*	3	0.8

\*Saudi Arabian Riyals

Table 3 shows that the most commonly identified causes of renal failure were diabetes mellitus (23%) and hypertension (21.9%). On the same line, it was found that the overwhelming

majorities of the patients (93.9 %) were currently hypertensive and a considerable proportion (39.6%) were currently diabetic. One half of the patients (50.3%) were on dialysis for 60 months or more and the majority (77%) had previous history of hospitalization. Clinically, the average number of co-morbidities accounted for 3.0 diseases; the median interdialytic weight gain was 2.0 kg; the average number of daily tablet(s) taken by patients was 5.0. The mean levels of pre- hemodialysis serum potassium (K<sup>+</sup>) and phosphorus (po<sub>4</sub>) were 5.1(0.9) mmol/L and 5.3(1.8) mg/dl; respectively.

**Table 3**

Clinical characteristics of the study group (n=361)

Characteristics	Frequency	%	
Causes of renal failure	Hypertension	79	21.9
	Diabetes mellitus	83	23.0
	Glomerulonephritis	13	3.6
	Others	69	19.1
	Unknown	117	32.4
Medical history	Kidney transplant	23	6.4
	HTN	339	93.9
	D.M	143	39.6
	Psychiatric disease	37	10.2
Duration of dialysis (months)	12 months or less	57	15.9
	13 to 36 months	76	21.2
	37 to 60 months	45	12.6
	60 months or greater	180	50.3
	Median	60	
Hospitalization history	278	77.0	
Number of comorbidities	Median	3.0	
Number of daily tablets	Median	5.0	
Interdialytic weight gain	Median	2.0 Kg	
Pre-hemodialysis serum potassium	Mean (SD)	5.1 (0.9) mmol/L	
	Range	2.7 – 10.2	
Pre-hemodialysis serum phosphorus	Mean (SD)	5.3 (1.8) mg/dl	
	Range	1.3 – 11.6	

Table 4 demonstrates that the overall prevalence of anti-HCV among HD patients was almost one half (49.9%) according to clinical measurements and questionnaires.

**Table 4**

Prevalence of HCV infection (n=361)

HCV indicators	HCV status	Frequency	%
Questionnaire	Positive	180	49.9%
	Negative	181	50.1%
Clinical measurement	Positive	180	49.9%
	Negative	181	50.1%

## 5. Discussion

HD patients are at high risk for hepatitis viral infections especially for HCV infection, [55] which has been reported from different parts of the world as a common infection, have a high prevalence rate and now recognized as the principal cause of liver disease among HD patients [56] [19].

Prevalence of HBV and HCV in HD patients were reported by several authors ranging between 0.9% to 21.6% for HBV[57, 58] and 3.4% to 65.8% for HCV[59-61]. There is a wide range in prevalence rates of HCV infection among HD patients in different regions of the world, ranging from 1% in the UK to more than 90% in Eastern Europe[5, 62-69].

In the current study, we observed a high prevalence of HCV antibody among patients undergoing HD at different centers in Makah city. The overall anti-HCV prevalence among HD patients in Makah city (49.9%) was comparable to that reported from other parts of KSA. It is almost similar to the already reported positivity rate of (43.2%) from the eastern region of KSA [70] and southern regions of KSA (45.5%) [34, 71]. It is much lower than that reported from other centers in KSA. It is lower than that reported by Shaheen *et al* [34, 36], from four centers in the Western region of KSA, (72.3%) and that by Huraib *et al* [72] [29] in their multi-center study in KSA, (68%) as well as the mean national rate[34, 73]. However, this value is higher than those observed in the central region of KSA[74].

Strict adherence to universal precautions as recommended by the CDC and meticulous regular disinfection of HD machines, Strict isolation of HCV- positive patients, dedicated dialysis machines and nursing staff at new dialysis set-up could possibly be the reasons of relatively low anti-HCV positivity at the current study.

The use of more sensitive third generation ELISA technique in our study could partially explain our higher prevalence rate than that reported earlier by Saeed *et al* [30] from Riyadh. Factors related to infrastructure and operational system might be responsible for the very high prevalence of anti-HVC found in this study.

Dialysis treatment could be a specific independent risk factor for HCV transmission as cross infection and could be responsible for high prevalence of anti-HCV positivity in HD patients in the current study. The reported annual seroconversion rate of 7-9% among HD patients of KSA.[75] The positive correlation of anti-HCV positivity with duration on HD coupled with 4.8% positivity among patients who had never been transfused, indicate strong possibility of nosocomial transmission of HCV, these observations have been reported from multiple HD centers. [5, 76, 77] Hence, the importance of strict adherence to universal infection control precautions should be emphasized in all the HD centers.

Blood transfusions could be responsible for the high prevalence of anti-HCV found in the current study. Blood transfusions can be a source for anti-HCV positivity according to reports [78][79] though reports to the contrary also exist [80]. However, data on correlation between anti-HCV positivity and history of blood transfusion in dialysis patients is conflicting. Whereas, some workers reported positive correlation [34, 35, 67, 79] others found none[81, 82]. Nevertheless, HCV transmission through blood transfusion should be considered since the reported prevalence of anti-HCV antibody in healthy blood donors varies from 0.42% in Germany [83] up to 6.6% in China [84]. The overall prevalence of anti-HCV among voluntary blood donors in KSA is about 2.2% [85]. Thus, screening of blood donors for anti-HCV is essential and those with positive results should be rejected. Studies confirmed that administration of blood products is the main risk factor for developing hepatitis C[5, 62, 66] [68, 86, 87]. But duration of HD in patients with or without blood transfusions is also an independent risk factor[68, 81, 86, 88]. Thus patient to patient transmission during HD has been suggested[89-93]. Patient to patient transmission was prospectively proved in several incidence studies in HD patients[91-93]. Repeated blood transfusions is a risk factor for HCV transmission. However, data on correlation between anti-HCV positivity and number of blood transfusions is inconclusive. In some studies, a positive correlation with blood transfusion has been reported [67, 94] while others have refuted this possibility [81, 82]. An increased prevalence of anti-HCV positivity among patients on HD for longer periods of time has been reported[95, 96].

Cross-infection could be responsible for the high prevalence of anti-HCV in HD patients in this study. Hence, the dialysis staff should observe all necessary precautions to prevent this. The allocation of separate HD machines for the anti-HCV positive patients could pose a real problem because of the large number of these patients. Since machine to patient transmission is not very well documented up to now, machine isolation may not be justified at the moment.

While the exact mode of HCV transmission through dialysis remains to be elucidated, it is reasonable to designate separate dialysis machines for anti-HCV positive patients. It would be of interest to follow-up the seronegative patients to see the impact of their isolation on seroconversion rate.

Nosocomial transmission of HCV and HBV is an important contributing factor to the spread of these viruses[97, 98]. Despite various infection control procedures in HD patients prevalence and incidence rates of HBV and HCV are still significant [99, 100]. Studies have shown that strict aseptic measures can virtually eliminate HCV contamination, even in units with a high prevalence of HCV infection.[101] It is known that different methods of control, cleaning and disinfection of the HD membranes, machines, instruments and environmental surfaces may interfere with determined prevalence[97].

Although the route of HCV transmission in HD patients is not yet fully elucidated, previous studies suggested that dialytic age and number of blood transfusions are closely associated with HCV seropositivity patients with dialysis treatment in multi-centers are also more prone to acquiring HCV infection[102,103]. Contaminated HD-machines, dialyzers, bloodline surfaces and hands of the caring staff and possibly, sharing of multi-dose heparin vials, are the possible factors that can contribute to the transmission of HCV among the multi-center visitors.

Non-uniform adherence to the universal precautions and disinfection procedures in different centers as well as practice of dialyzing both HCV positive and negative patients in the same room, with or without separate machines, might be the underlying reasons to make these patients more prone to acquire HCV. However, dialysis of HCV positive patients in a separate designated room is not recommended by the CDC[104]. Multivariate analysis has revealed that seropositivity of HCV increases with the increased dialytic age of the patient and the number of blood transfusions. However, reports to the contrary have also been published regarding the association of blood transfusion and HCV transmission[105, 106]. Increased nosocomial transmission due either to prolonged immunocompromized state or breaches in the universal infection control measures during dialytic age, may be the factors responsible for this. Recently, nosocomial transmission of HCV among HD patients has been documented by the molecular analysis[107, 108] which raises the question of how HCV- positive patients should be handled in dialysis units. Although, it has been showed that 50-70% of HCV-positive patients progress, over a period of 10-40 years, to chronic hepatitis with increased risk of cirrhosis, liver failure and liver cancer[43] the longterm outcome of untreated patients chronic HCV infection having normal or elevated liver enzymes is still unknown.

## 5. Conclusions

In conclusion, this cross-sectional study was designed to identify the prevalence of anti-HCV in HD patients in Makkah city since they are at high risk for HCV infection. The overall prevalence of anti-HCV among HD patients in Makkah city (49.9%) was comparable to that reported from other parts of KSA and it is almost similar to the already reported positivity rate of (43.2%) from the eastern region of KSA [70] and southern regions of KSA (45.5%) [34, 71]. However, Strict adherence to universal precautions as recommended by the CDC, meticulous regular disinfection of HD machines, Strict isolation of HCV-positive patients, dedicated dialysis machines and nursing staff at new dialysis



set-up could possibly be the reasons of relatively low anti-HCV positivity at the current study than that reported by Shaheen *et al* [34, 36], from four centers in the Western region of KSA, (72.3%) and that by Huraib *et al* [72] [29] in their multi-center study in KSA, (68%) as well as the mean national rate [34, 73]. On the other hand, the use of more sensitive third generation ELISA technique, long duration on HD, multiple blood transfusions, patients with dialysis treatment in multi-centers, factors related to infrastructure, environment and operational system might be responsible for the high prevalence of anti-HCV found in this study than that reported earlier by Saeed *et al* [30] from Riyadh and those observed in the central region of KSA [74].

## 6. Recommendations

This study recommends health leaders to improve the economic status of HD patients who need that support because almost two thirds of the patients (60.1%) had monthly income between 1000 and 3000 SAR. Since the great majorities (88.9%) of HD patients at the HD centers are unemployed, a subsidized support system must be initiated to support these patients; Social agencies and charitable organizations can collaborate with HD centers in this effort.

As the current study showed a high prevalence of anti-HCV among HD patients [almost one half (49.9%) of them were anti-HCV positive] in Makkah city, frequent measurement of prevalence of anti-HCV for them should be carried out in all HD centers in Makkah city and other parts of KSA.

Further qualitative and quantitative research into effective ways are needed by using different research designs to identify the prevalence of anti-HCV among HD patients in Makkah city and other parts of KSA. The results of these research are better to be compared with results of this study. These research must continue in order to improve outcomes among HD patients.

Efforts should be done to identify factors associated with HCV infection in Makkah city and other parts of KSA in order to decrease them as those factors constitutes a major health problem for HD patients. However, in most European countries, consistent reinforcement of hygienic precautions and/or isolation strategies in HD units has resulted in a substantial decrease of both the incidence and prevalence of HCV infection in HD units [109]. So, we must concentrate more on those factors in addition to factors related to infrastructure, environment and operational system.

More detailed studies are required to know the exact mode of spread of HCV so that appropriate measures may be taken to prevent this serious disease from spreading. However, an intensive educational program for staff members and proper evaluation of the HD situation are needed. Thus, observation of appropriate preventive measures by all the HD-centers is paramount.

Strict adherence to the universal precautions combined with proper disinfection procedures and increasing awareness among the HD staff and patients may reduce the spread of HCV infection in the dialysis units. Furthermore, as routes of transmission are still unclear, early detection of all infected patients is mandatory for HCV prophylaxis in HD patients. This early detection of HCV infection is important in patients undergoing HD because of the high prevalence of infection among them [110]. This early detection could result in better management of patients and a reduction in patient-to-patient transfer of HCV infection in HD units [110].

## References

- [1] Choo, Qui-Lim, George Kuo, Amy J. Weiner, Lacy R. Overby, Daniel W. Bradley, and Michael Houghton. "Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome." *Science* 244, no. 4902 (1989): 359-362.
- [2] Centers for Disease Control and Prevention. "Recommendations for preventing transmission of infections among chronic hemodialysis patients." *MMWR* 50 (2001): 1-43.

- [3] De Medina, Maria, Melanie Ashby, Volker Schluter, Mary Hill, Baudouin Leclercq, J. Phillip Pennell, Lennox J. Jeffers et al. "Prevalence of hepatitis C and G virus infection in chronic hemodialysis patients." *American journal of kidney diseases* 31, no. 2 (1998): 224-226.
- [4] Alter, Miriam J., and Harold S. Margolis. "Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease." (1998).
- [5] Knudsen, Freddy, Per Wantzin, Knud Rasmussen, Søren D. Ladefoged, Niels Løkkegaard, Lars S. Rasmussen, Anders Lassen, and Kim Krogsgaard. "Hepatitis C in dialysis patients: Relationship to blood transfusions, dialysis and liver disease." *Kidney international* 43, no. 6 (1993): 1353-1356.
- [6] Cuthbert, Jennifer A. "Southwestern internal medicine conference: hepatitis C." *The American journal of the medical sciences* 299, no. 5 (1990): 346-355.
- [7] Lauer, Georg M., and Bruce D. Walker. "Hepatitis C virus infection." *New England journal of medicine* 345, no. 1 (2001): 41-52.
- [8] Bukh, Jens, Per Wantzin, Kim Krogsgaard, Freddy Knudsen, Robert H. Purcell, Roger H. Miller, and Copenhagen Dialysis HCV Study Group. "High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection." *Journal of Infectious Diseases* 168, no. 6 (1993): 1343-1348.
- [9] Fabrizi, Fabrizio, F. Fred Poordad, and Paul Martin. "Hepatitis C infection and the patient with end-stage renal disease." *Hepatology* 36, no. 1 (2002): 3-10.
- [10] Bassit, L., H. Van Heuverswyn, K. De Bosschere, A. Nishiya, F. J. Carrilho, C. Moraes, and E. Sablon. "Comparative study of two anti-HCV screening tests in a large genotyped population of Brazilian dialysis patients." *European Journal of Clinical Microbiology and Infectious Diseases* 21, no. 5 (2002): 404.
- [11] Fabrizi, F., G. Lunghi, I. Guarneri, L. Raffaele, S. Di Filippo, G. Erba, A. Pagano, and F. Locatelli. "Virological characteristics of hepatitis C virus infection in chronic hemodialysis patients: a cross-sectional study." *Clinical nephrology* 44, no. 1 (1995): 49-55.
- [12] Nakayama, Eijun, Takashi Akiba, Fumiaki Marumo, and Chifumi Sato. "Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy." *Journal of the American Society of Nephrology* 11, no. 10 (2000): 1896-1902.
- [13] Maisonneuve, Patrick, Lawrence Agodoa, Ryszard Gellert, John H. Stewart, Gheardo Buccianti, Albert B. Lowenfels, Robert A. Wolf et al. "Cancer in patients on dialysis for end-stage renal disease: an international collaborative study." *The Lancet* 354, no. 9173 (1999): 93-99.
- [14] Hanafusa, Tsuru, Yasuji Ichikawa, Hidefumi Kishikawa, Masahiro Kyo, Takanobu Fukunishi, Yukito Kokado, Akihiko Okuyama, Yoshitake Shinji, and Shunsuke Nagano. "Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years." *Transplantation* 66, no. 4 (1998): 471-476.
- [15] Mathurin, Philippe, Catherine Mouquet, Thierry Poynard, Cheickna Sylla, Hadjira Benalia, Catherine Fretz, Vincent Thibault et al. "Impact of hepatitis B and C virus on kidney transplantation outcome." *Hepatology* 29, no. 1 (1999): 257-263.
- [16] Venkateswara Rao, K., and J. Ma. "Chronic viral hepatitis enhances the risk of infection but not acute rejection in renal transplant recipients." *Transplantation* 62, no. 12 (1996): 1765-1769.
- [17] Alter, Harvey J. "Transmission patterns in hepatitis C virus infection." In *Viral hepatitis and liver disease*, pp. 445-449. Springer, Tokyo, 1994.
- [18] Young, Eric W., David A. Goodkin, Donna L. Mapes, Friedrich K. Port, Marcia L. Keen, Kenneth Chen, Bradley L. Maroni, Robert A. Wolfe, and Philip J. Held. "The dialysis outcomes and practice patterns study (DOPPS): an international hemodialysis study." *Kidney International* 57 (2000): S74-S81.
- [19] Fabrizi, Fabrizio, Paul Martin, Vivek Dixit, Maria Brezina, Mary J. Cole, Steve Vinson, Mariam Mousa, and Gary Gitnick. "Biological dynamics of viral load in hemodialysis patients with hepatitis C virus." *American journal of kidney diseases* 35, no. 1 (2000): 122-129.
- [20] Conlon, P. J., J. J. Walshe, E. G. Smyth, E. B. McNamara, J. Donohoe, and M. Carmody. "Lower prevalence of anti-hepatitis C antibody in dialysis and renal transplant patients in Ireland." *Irish journal of medical science* 162, no. 4 (1993): 145-147.
- [21] Mondelli, M. U., G. Cristina, V. Piazza, A. Cerino, G. Villa, and A. Salvadeo. "High prevalence of antibodies to hepatitis C virus in hemodialysis units using a second generation assay." *Nephron* 61, no. 3 (1992): 350-351.
- [22] Othman, B., and F. Monem. "Prevalence of antibodies to hepatitis C virus among hemodialysis patients in Damascus, Syria." *Infection* 29, no. 5 (2001): 262-265.
- [23] Soetjijpto, R. Handajani, M. I. Lusida, S. Darmadi, P. Adi, Soemarto, S. Ishido, Y. Katayama, and H. Hotta. "Differential prevalence of hepatitis C virus subtypes in healthy blood donors, patients on maintenance hemodialysis, and patients with hepatocellular carcinoma in Surabaya, Indonesia." *Journal of clinical microbiology* 34, no. 12 (1996): 2875-2880.

- [24] Schneeberger, Peter M., Ingrid Keur, Walter van der Vliet, Kitty van Hoek, Henk Boswijk, Anton M. van Loon, Willemien C. van Dijk, Robert H. Kauffmann, Wim Quint, and Leen-Jan van Doorn. "Hepatitis C virus infections in dialysis centers in The Netherlands: a national survey by serological and molecular methods." *Journal of Clinical Microbiology* 36, no. 6 (1998): 1711-1715.
- [25] Karohl, Cristina, Roberto Ceratti Manfro, Martha Bergman Senger, F. Saldanha Thomé, LF Santos Gonçalves, Marília Rigatto, and Carlos Alberto Prompt. "Prevalência de anticorpos anti-vírus da hepatite C em pacientes em hemodiálise crônica de Porto Alegre." *J Bras Nefrol* 17, no. 1 (1995): 40-6.
- [26] Vanderborght, B. O. M., C. Rouzere, C. F. Ginuino, G. Maertens, H. Van Heuverswyn, and C. F. T. Yoshida. "High prevalence of hepatitis C infection among Brazilian hemodialysis patients in Rio de Janeiro: a one-year follow-up study." *Revista do Instituto de Medicina Tropical de São Paulo* 37 (1995): 75-79.
- [27] Naghettini, Alessandra Vitorino, Roberto Ruhman Daher, Regina Martin, Jarbas Doles, Bart Vanderborght, Clara FT Yoshida, and Caroline Rouzere. "Soroprevalência do vírus da hepatite C na população em diálise de Goiânia, GO." *Revista da Sociedade Brasileira de Medicina Tropical* 30 (1997): 113-117.
- [28] Góngora, Delzi Vinha Nunes de. "Marcadores sorológicos da infecção pelo vírus da hepatite C em trabalhadores e pacientes da Unidade de Diálise do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo." *Revista da Sociedade Brasileira de Medicina Tropical* 31 (1998): 585-586.
- [29] Huraib, S., R. Al-Rasheed, A. Aldrees, M. Al Jefry, M. Arif, and F. A. Faleh. "High prevalence and risk factors for hepatitis C in Saudi Arabia: a need for new strategies in dialysis practice." *Nephrol Dial Transplant* 10, no. 4 (1995): 470-4.
- [30] Saeed, A. A., D. Fairclough, AM ALADMAWI, R. Bacchus, A. O. Osoba, AM ALRASHEED, AA ALHILALI et al. "HEPATITIS-C VIRUS IN SAUDI-ARABIA-A PRELIMINARY SURVEY." *Saudi Medical Journal* 11, no. 4 (1990): 331-332.
- [31] Fakunle, Yisa M., Mohammed Al-Mofarreh, Wafaa M. El-Karamany, Handy O. Ezzat, Badr Al-Shora, and Abdallah Z. El-Drees. "Prevalence of antibodies to hepatitis C virus in hemodialysis patients in Riyadh." *Annals of Saudi Medicine* 11, no. 5 (1991): 504-506.
- [32] Fathalla, S. E., and AA ALJAMA. "PREVALENCE OF HEPATITIS-C VIRAL ANTIBODIES IN BLOOD-DONORS, PREGNANT-WOMEN AND HEMODIALYSIS-PATIENTS IN THE EASTERN PROVINCE OF SAUDI-ARABIA-A PRELIMINARY-STUDY." *Saudi Medical Journal* 14, no. 3 (1993): 265-265.
- [33] Nasser, MN Al, MA Al Mugeiren, S. A. Assuhaimi, E. Obineche, J. Onwabalili, and S. Ramia. "Seropositivity to hepatitis C virus in Saudi haemodialysis patients." *Vox sanguinis* 62, no. 2 (1992): 94-97.
- [34] Shaheen, Faissal AM, Sameer O. Huraib, Rashed Al-Rashed, Abdulatif Aldrees, Mohammad Arif, Mohammad Al Jeffry, Mohammad Amin Tashkandy, and Mohamad Safwat. "Prevalence of hepatitis C antibodies among hemodialysis patients in the Western province of Saudi Arabia." *Saudi Journal of Kidney Diseases and Transplantation* 6, no. 2 (1995): 136.
- [35] Huraib, S., R. Al-Rashed, A. Aldrees, M. Aljefry, M. Arif, and F. A. Al-Faleh. "High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: a need for new dialysis strategies." *Nephrology Dialysis Transplantation* 10, no. 4 (1995): 470-474.
- [36] Al Shohaib, Saad S., Mohamed A. Abdelaal, Tarif H. Zawawi, Fatima M. Abbas, Faissal AM Shaheen, and Essife Amoah. "The prevalence of hepatitis C virus antibodies among hemodialysis patients in Jeddah area, Saudi Arabia." *Saudi Journal of Kidney Diseases and Transplantation* 6, no. 2 (1995): 128.
- [37] Muller, Grete Y., Mercedes E. Zabaleta, Anabella Arminio, Carmen J. Colmenares, Freya I. Capriles, Nicolás E. Bianco, and Irma V. Machado. "Risk factors for dialysis-associated hepatitis C in Venezuela." *Kidney international* 41, no. 4 (1992): 1055-1058.
- [38] Marschall S. Runge, C.P., *Principles of Molecular Medicine*. 2 ed. 18-11-2007: Springer Science & Business Media. 1268.
- [39] Debure, A., C. Legendre, H. Kreis, C. Degott, F. Carnot, S. Pol, and C. Brechot. "Chronic hepatitis in kidney allograft recipients." *The Lancet* 335, no. 8694 (1990): 878-880.
- [40] Bruguera, M., L. Vidal, J. M. Sanchez-Tapias, J. Costa, L. Revert, and J. Rodes. "Incidence and features of liver disease in patients on chronic hemodialysis." *Journal of clinical gastroenterology* 12, no. 3 (1990): 298-302.
- [41] Cuthbert, J. A. "Erratum: Hepatitis a: Old and new (clinical microbiology reviews (2001) 14: 1 (38-58))." *Clinical Microbiology Reviews* 14, no. 3 (2001).
- [42] Kew, M. C., M. Houghton, Q. L. Choo, and G. Kuo. "Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma." *The Lancet* 335, no. 8694 (1990): 873-874.
- [43] Kew, M. C., M. Houghton, Q. L. Choo, and G. Kuo. "Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma." *The Lancet* 335, no. 8694 (1990): 873-874.
- [44] Wright, T.L., *Hepatitis C virus infection and organ transplantation*. Prog Liver Dis, 1993. 11: p. 215-30.
- [45] Wright, T., *Hepatitis C virus infection and organ transplantation*. Progress in liver diseases, 1993. 11: p. 215-230.

- [46] Roth, David, John A. Fernandez, Sharon Babischkin, Angelo De Mattos, B. E. Buck, Stella Quan, Les Olson et al. "Detection of hepatitis C virus infection among cadaver organ donors: evidence for low transmission of disease." *Annals of internal medicine* 117, no. 6 (1992): 470-475.
- [47] Chan, Tak-Mao, Anna SF Lok, Ignatius KP Cheng, and Rachel T. Chan. "A prospective study of hepatitis C virus infection among renal transplant recipients." *Gastroenterology* 104, no. 3 (1993): 862-868.
- [48] Kalantar-Zadeh, Kamyar, Ryan D. Kilpatrick, Charles J. McAllister, Loren G. Miller, Eric S. Daar, David W. Gjertson, Joel D. Kopple, and Sander Greenland. "Hepatitis C virus and death risk in hemodialysis patients." *Journal of the American Society of Nephrology* 18, no. 5 (2007): 1584-1593.
- [49] Moyer, Linda A., and Miriam J. Alter. "Hepatitis C virus in the hemodialysis setting: a review with recommendations for control." In *Seminars in Dialysis*, vol. 7, no. 2, pp. 124-127. Oxford, UK: Blackwell Publishing Ltd, 1994.
- [50] Blumberg, A., C. Zehnder, and J. J. Burckhardt. "Prevention of hepatitis C infection in haemodialysis units. A prospective study." *Nephrology Dialysis Transplantation* 10, no. 2 (1995): 230-233.
- [51] Simon, N., et al., *A twelve year natural history of hepatitis C virus infection in hemodialyzed patients*. *Kidney Int*, 1994. 46(2): p. 504-11.
- [52] Guh, Jinn-Yuh, Yung-Hsiung Lai, Chi-Yuan Yang, Shinn-Cherng Chen, Wan-Long Chuang, Tzu-Chao Hsu, Hung-Chun Chen, Wen-Yu Chang, and Juei-Hsiung Tsai. "Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients." *Nephron* 69, no. 4 (1995): 459-465.
- [53] Fabrizi, F., G. Lunghi, S. Andrulli, B. Pagliari, S. Mangano, P. Faranna, A. Pagano, and F. Locatelli. "Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients." *Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association* 12, no. 7 (1997): 1394-1398.
- [54] Stehman-Breen, Catherine O., Scott Emerson, David Gretch, and Richard J. Johnson. "Risk of death among chronic dialysis patients infected with hepatitis C virus." *American Journal of Kidney Diseases* 32, no. 4 (1998): 629-634.
- [55] Hosseini-Moghaddam, Seyed Mohammadmehdi, Hossein Keyvani, Hossein Kasiri, Seyed Mohammad Kazemeyni, Abbas Basiri, Nazanin Aghel, and Seyed-Moayed Alavian. "Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran—a multicenter study." *Journal of medical virology* 78, no. 5 (2006): 569-573.
- [56] Cotler, Scott J., Gloria Diaz, Sushama Gundlapalli, Shiram Jakate, Anshuman Chawla, Deepak Mital, Steven Jensik, and Donald M. Jensen. "Characteristics of hepatitis C in renal transplant candidates." *Journal of clinical gastroenterology* 35, no. 2 (2002): 191-195.
- [57] Schneeberger, Peter M., Ingrid Keur, Anton M. van Loon, Daniella Mortier, Katja Op de Coul, Anita Verschuuren-van Haperen, Ricardo Sanna et al. "The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study." *The Journal of infectious diseases* 182, no. 5 (2000): 1291-1299.
- [58] Todorov, V., R. Boneva, P. Ilieva, T. Doichinova, and M. Donchev. "High prevalence of hepatitis c virus in one dialysis center in bulgaria." *Nephron* 79, no. 2 (1998): 222.
- [59] Tokars, J.I., et al. *National surveillance of dialysis-associated diseases in the United States, 2000*. in *Seminars in dialysis*. 2002. Wiley Online Library.
- [60] Vladutiu, D. S., A. Cosa, A. Neamtu, M. Braila, M. Gherman, I. M. Patiu, and I. Dulau-Florea. "Infections with hepatitis B and C viruses in patients on maintenance dialysis in Romania and in former communist countries: yellow spots on a blank map?." *Journal of viral hepatitis* 7, no. 4 (2000): 313-319.
- [61] Somi, Mohammad H., Hussein Keivani, Mohammad R. Ardalani, Sara Farhang, and Ali A. Pouri. "Hepatitis C virus genotypes in patients with end-stage renal disease in East Azerbaijan, Iran." *Saudi Journal of Kidney Diseases and Transplantation* 19, no. 3 (2008): 461.
- [62] Alter, Miriam J. "Epidemiology of hepatitis C in the West." In *Seminars in liver disease*, vol. 15, no. 01, pp. 5-14. © 1995 by Thieme Medical Publishers, Inc., 1995.
- [63] Chan, Tak Mao, Anna Suk Fong Lok, Ignatius Kum Po Cheng, and Rachel Tzun Chan. "Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays." *Hepatology* 17, no. 1 (1993): 5-8.
- [64] Courouce, A-M., F. Bouchardeau, P. Chauveau, N. Le Marrec, A. Girault, B. Zins, C. Naret, and J-L. Poinet. "Hepatitis C virus (HCV) infection in haemodialysed patients: HCV-RNA and anti-HCV antibodies (third-generation assays)." *Nephrology Dialysis Transplantation* 10, no. 2 (1995): 234-239.
- [65] McIntyre, P. G., E. A. B. McCrudden, B. C. Dow, S. O. Cameron, M. A. McMillan, M. E. M. Allison, and J. D. Briggs. "Hepatitis C virus infection in renal dialysis patients in Glasgow." *Nephrology Dialysis Transplantation* 9, no. 3 (1994): 291-295.

- [66] Medin, Charlotte, Tobias Allander, Martin Roll, Stefan H. Jacobson, and Lena Grillner. "Seroconversion to hepatitis C virus in dialysis patients: a retrospective and prospective study." *Nephron* 65, no. 1 (1993): 40-45.
- [67] Dentico, P., R. Buongiorno, A. Volpe, A. Carlone, M. Carbone, C. Manno, F. Proscia, G. Pastore, and O. Schiraldi. "Prevalence and incidence of hepatitis C virus (HCV) in hemodialysis patients: study of risk factors." *Clinical nephrology* 38, no. 1 (1992): 49-52.
- [68] Jadoul, Michel, Chantal Cornu, and Charles van Ypersele de Strihou. "Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study." *Kidney international* 44, no. 6 (1993): 1322-1326.
- [69] Covic, Adrian, Luminita Iancu, Cristian Apetrei, Didona Scripcaru, Carmen Volovat, Irina Mititiuc, and Maria Covic. "Hepatitis virus infection in haemodialysis patients from Moldavia." *Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association* 14, no. 1 (1999): 40-45.
- [70] Al-Muhanna, Fahad A. "Hepatitis C virus infection among hemodialysis patients in the eastern region of Saudi Arabia." *Saudi Journal of Kidney Diseases and Transplantation* 6, no. 2 (1995): 125.
- [71] Saxena, Anil K., B. R. Panhotra, Mohamed Naguib, Mohammed Nabil Aboras, D. S. Sundaram, C. K. Venkateshappa, and Wahid Uzzaman Khan. "Prevalence of hepatitis C antibodies among hemodialysis patients in Al-Hasa region of Saudi Arabia." *Saudi Journal of Kidney Diseases and Transplantation* 12, no. 4 (2001): 562.
- [72] Huraib, S., R. Al-Rashed, A. Aldrees, M. Aljefry, M. Arif, and F. A. Al-Faleh. "High prevalence of and risk factors for hepatitis C in haemodialysis patients in Saudi Arabia: a need for new dialysis strategies." *Nephrology Dialysis Transplantation* 10, no. 4 (1995): 470-474.
- [73] Khan, L. A., and S. A. Khan. "Prevalence of hepatitis B and C markers in patients on maintenance hemodialysis in Najran." *Saudi Medical Journal* 22, no. 7 (2001): 641-642.
- [74] Anonymous, *Dialysis in the Kingdom of Saudi Arabia (SCOT data)*. Saudi J Kidney Dis Transplant 2001. **12**(3): p. 14.
- [75] Souqiyeh, Muhammed Ziad, Faissal AM Shaheen, Sameer O. Huraib, and Abdullah A. Al-Khader. "The annual incidence of seroconversion of antibodies to the hepatitis C virus in the hemodialysis population in Saudi Arabia." *Saudi Journal of Kidney Diseases and Transplantation* 6, no. 2 (1995): 167.
- [76] Teruel, J. L., J. Pascual, F. Liano, and J. Ortuno. "Importance of nosocomial transmission of hepatitis C virus infection in dialysis units." *Clinical nephrology* 38, no. 4 (1992): 232-233.
- [77] Favero, M. S. "Dialysis-associated infections and their control." *Hospital infections* (1992): 375-403.
- [78] Pauri, P., G. Salvoni, W. Vitolo, P. Carletti, E. Fanciulli, A. M. Ricciatti, Della Bella, and V. A. Mioli. "Risk factors and clinical expression of HCV infection in hemodialysis patients." *Nephron* 61, no. 3 (1992): 313-314.
- [79] Van der Poel, C. L., H. W. Reesink, W. Schaasberg, E. Bakker, P. J. Exel-Oehlers, P. N. Lelie, and A. Leentvaar-Kuypers. "Infectivity of blood seropositive for hepatitis C virus antibodies." *The Lancet* 335, no. 8689 (1990): 558-560.
- [80] Pluvio, M., A. Saggese, D. Cirillo, P. Castellino, R. Pempinello, M. D. Iannece, D. Guarnaccia et al. "Hepatitis C virus-related acute and chronic hepatitis in hemodialysis patients." *Nephron* 61, no. 3 (1992): 322-323.
- [81] Hardy, N. M., S. Sandroni, S. Danielson, and W. J. Wilson. "Antibody to hepatitis C virus increases with time on hemodialysis." *Clinical nephrology* 38, no. 1 (1992): 44-48.
- [82] Vitale, C., A. Tricerri, M. Marangell, G. M. Vacha, G. Giorcelli, C. Marini, G. Molinaro, D. Cosseddu, and F. Linari. "Epidemiology of hepatitis C virus infection in dialysis units: first-versus second-generation assays." *Nephron* 64, no. 2 (1993): 315-316.
- [83] Kuhn, P. S. W. J. W. H., S. Seidl, W. Stangel, J. Beyer, W. Sibrowski, and J. Flik. "Antibody to hepatitis C virus in German blood donors." *Lancet* 2, no. 8658 (1989): 324-324.
- [84] Tao, Qi-min, Yu Wang, Hao Wang, Wei-ran Chen, Yan Sun, and Qin Meng. "Investigation of anti-HCV in 391 serum samples in China." *Chinese Medical Journal* 103, no. 08 (1990): 616-618.
- [85] Al-Mofarreh, Mohammed, Yisa M. Fakunle, Wafaa M. El-Karamany, Handy O. Ezzat, Maria N. Ballesteros, Mohammed Z. Khawaji, and Abdallah Z. El-Drees. "Prevalence of antibodies to hepatitis C virus in blood donors in Riyadh." *Annals of Saudi medicine* 11, no. 5 (1991): 501-503.
- [86] Lallo, Domenico Di, Maria Miceli, Nicola Petrosillo, Carlo A. Perucci, and Marina Moscatelli. "Risk factors of hepatitis C virus infection in patients on hemodialysis: a multivariate analysis based on a dialysis register in Central Italy." *European journal of epidemiology* 15, no. 1 (1999): 11-14.
- [87] Salama, Gilles, Lionel Rostaing, Karine Sandres, and Jacques Izopet. "Hepatitis C virus infection in French hemodialysis units: a multicenter study." *Journal of medical virology* 61, no. 1 (2000): 44-51.
- [88] Okuda, Kunio, Haruyuki Hayashi, Susumu Kobayashi, and Yasubumi Irie. "Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients." *Journal of hepatology* 23, no. 1 (1995): 28-31.

- [89] Fabrizi, Fabrizio, Paul Martin, Vivek Dixit, Maria Brezina, Mary J. Cole, Silvia Gerosa, Mariam Mousa, and Gary Gitnick. "Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay." *American journal of kidney diseases* 31, no. 4 (1998): 647-654.
- [90] Fabrizi, Fabrizio, Paul Martin, Vivek Dixit, Maria Brezina, James Russell, Andy Conrad, Peter Schmid, Silvia Gerosa, and Gary Gitnick. "Detection of de novo hepatitis C virus infection by polymerase chain reaction in hemodialysis patients." *American journal of nephrology* 19, no. 3 (1999): 383-388.
- [91] Irish, Dianne N., Catherine Blake, Jackie Christophers, John E. Craske, Lisa Burnapp, Ian C. Abbs, Eithne ME MacMahon, Peter Muir, Jangu E. Banatvala, and Peter Simmonds. "Identification of hepatitis C virus seroconversion resulting from nosocomial transmission on a haemodialysis unit: implications for infection control and laboratory screening." *Journal of medical virology* 59, no. 2 (1999): 135-140.
- [92] Katsoulidou, Antigoni, Dimitrios Paraskevis, Victoria Kalapothaki, Dimitrios Arvanitis, P. Karayiannis, V. Hadjiconstantiou, and A. Hatzakis. "Molecular epidemiology of a hepatitis C virus outbreak in a haemodialysis unit. Multicentre Haemodialysis Cohort Study on Viral Hepatitis." *Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association* 14, no. 5 (1999): 1188-1194.
- [93] Mizuno, Mari, Terumi Higuchi, Katsuo Kanmatsuse, and Mariko Esumi. "Genetic and serological evidence for multiple instances of unrecognized transmission of hepatitis C virus in hemodialysis units." *Journal of clinical microbiology* 36, no. 10 (1998): 2926-2931.
- [94] Ayoola, E. A., S. Huraib, M. Arif, F. Z. Al-Faleh, R. Al-Rashed, S. Ramia, I. A. Al-Mofleh, and H. Abu-Aisha. "Prevalence and significance of antibodies to hepatitis C virus among Saudi haemodialysis patients." *Journal of medical virology* 35, no. 3 (1991): 155-159.
- [95] Giammaria, U., F. De Meo, S. Acitelli, M. Tancredi, M. Daniele, R. Barnabei, and C. Maschio. "HCV infection in hemodialyzed patients: incidence and correlation with dialytic age." *Nephron* 61, no. 3 (1992): 335-336.
- [96] OGUCHI, HISAO, MASUO TERASHIMA, SHINICHI TOKUNAGA, KENDO KIYOSAWA, EIJI TANAKA, SEIICHI FURUTA, YUTAKA KANNO, TAKAO AIZAWA, and KUSUYA NISHIOKA. "Prevalence of anti-HCV in patients on long-term hemodialysis." *The Japanese Journal of Nephrology* 32, no. 3 (1990): 313-317.
- [97] Busek, Solange U., Élio H. Babá, Hélcio A. Tavares Filho, Lermínio Pimenta, Abraão Salomão, Rodrigo Corrêa-Oliveira, and Guilherme C. Oliveira. "Hepatitis C and hepatitis B virus infection in different hemodialysis units in Belo Horizonte, Minas Gerais, Brazil." *Memórias do Instituto Oswaldo Cruz* 97 (2002): 775-778.
- [98] Carneiro, Megmar AS, Regina Martins, Sheila A. Teles, Simonne A. Silva, Carmen L. Lopes, Divina DP Cardoso, Bart OM Vanderborcht, and Clara FT Yoshida. "Hepatitis C prevalence and risk factors in hemodialysis patients in Central Brazil: a survey by polymerase chain reaction and serological methods." *Memórias do Instituto Oswaldo Cruz* 96 (2001): 765-769.
- [99] Souza, Karla P., Jônio A. Luz, Sheila A. Teles, Megmar AS Carneiro, Luciana A. Oliveira, Adriane S. Gomes, Márcia A. Dias, Selma A. Gomes, Clara FT Yoshida, and Regina MB Martins. "Hepatitis B and C in the hemodialysis unit of Tocantins, Brazil: serological and molecular profiles." *Memórias do Instituto Oswaldo Cruz* 98 (2003): 599-603.
- [100] Silva, Luciano Kalabric, M. B. S. Silva, Itatiana Ferreira Rodart, Gisele Barreto Lopes, F. Q. Costa, M. E. Melo, E. Gusmão, and Mitermayer Galvão dos Reis. "Prevalence of hepatitis C virus (HCV) infection and HCV genotypes of hemodialysis patients in Salvador, Northeastern Brazil." *Brazilian journal of medical and biological research* 39 (2006): 595-602.
- [101] Pereira, Brian JG. "Hepatitis C virus infection in dialysis: a continuing problem." *Artificial organs* 23, no. 1 (1999): 51-60.
- [102] Olmer, M., D. Bouchouareb, C. Zandotti, P. De Micco, and X. De Lamballerie. "Transmission of the hepatitis C virus in an hemodialysis unit: evidence for nosocomial infection." *Clinical nephrology* 47, no. 4 (1997): 263-270.
- [103] Kashem, Abul, Ibrahim Nusairat, Mirvat Mohamad, Mohamad Ramzy, Jaisimha Nemma, Mohd Rezaul Karim, M. P. Divakaran, and Abdul Shakoor Tayaab. "Hepatitis C virus among hemodialysis patients in Najran: prevalence is more among multi-center visitors." *Saudi Journal of Kidney Diseases and Transplantation* 14, no. 2 (2003): 206.
- [104] Saxena, Anil K., and B. R. Panhotra. "Nosocomial transmission of hepatitis C virus: impact of strict isolation on annual seroconversion rate in a hemodialysis unit." *Saudi Journal of Kidney Diseases and Transplantation* 13, no. 2 (2002): 186.
- [105] Lin, Hsien-Hong, Chiu-Ching Huang, I-Shyong Sheen, Deng-Yn Lin, and Yun-Fan Liaw. "Prevalence of antibodies to hepatitis C virus in the hemodialysis unit." *American journal of nephrology* 11, no. 3 (1991): 192-194.
- [106] Dandrani S, H.N., Danielson S, Wilson B., *Risk of hepatitis C increases with duration of dialysis (abstract)*. J Am Soc Nephrol, 1991. 2.
- [107] de Lamballerie, Xavier, Michel Olmer, Dammar Bouchouareb, Christine Zandotti, and Ph De Micco. "Nosocomial transmission of hepatitis C virus in haemodialysis patients." *Journal of medical virology* 49, no. 4 (1996): 296-302.

- [108] Grethe, Stefanie, Friederike Gemsa, Masyar Monazahian, Ingo Böhme, Angela Uy, and Reiner Thomssen. "Molecular epidemiology of an outbreak of HCV in a hemodialysis unit: Direct sequencing of HCV-HVR1 as an appropriate tool for phylogenetic analysis." *Journal of medical virology* 60, no. 2 (2000): 152-158.
- [109] Jadoul, Michel, and Guillermina Barril. "Hepatitis C in hemodialysis: epidemiology and prevention of hepatitis C virus transmission." *Hepatitis C in Renal Disease, Hemodialysis and Transplantation* 176 (2012): 35-41.
- [110] Méndez-Sánchez, Nahum, Daniel Motola-Kuba, Norberto C. Chavez-Tapia, Jesús Bahena, Ricardo Correa-Rotter, and Misael Uribe. "Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico." *Journal of clinical microbiology* 42, no. 9 (2004): 4321-4322.